Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30337202 | 1.00 | ALDH1A1 (0.39) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL30337358 | 0.83 | GAA (0.40) | ALDH1A1KDM4EMEN1KMT2AGAA | |
| SCHEMBL28987638 | 0.83 | GAA (0.40) | ALDH1A1KDM4EMEN1KMT2AGAA | |
| SCHEMBL30337199 | 0.82 | TEK (0.46) | ALDH1A1KMT2AHPGDCYP2C19HTT | |
| SCHEMBL17384806 | 0.82 | TEK (0.46) | ALDH1A1KMT2AHPGDCYP2C19HTT | |
| SCHEMBL19103283 | 0.81 | EGFR (0.41) | ALDH1A1MEN1KMT2AGPR3GLA | |
| SCHEMBL19103280 | 0.77 | KDM4E (0.47) | ALDH1A1KDM4EKMT2AHPGDHSD17B10 | |
| SCHEMBL31105657 | 0.77 | KDM4E (0.47) | ALDH1A1KDM4EKMT2AHPGDHSD17B10 | |
| SCHEMBL21165735 | 0.77 | KMT2A (0.40) | KDM4EKMT2AGAAHTTMAPT | |
| SCHEMBL22619772 | 0.76 | CHRM2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112457298-B | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-112375067-B | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-115974845-A | Preparation method of oxitinib intermediate | 奥锐特药业股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-11414401-B2 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | BETA PHARMA INC. (US) | 2022-08-16 | — | — | US | disclosed |
| CN-112457298-A | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-112375067-A | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-108024993-B | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20200216421-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200216421-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10590111-B2 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | BETA PHARMA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10590111-B2 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | BETA PHARMA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| CN-108024993-A | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2018-05-11 | — | — | CN | disclosed |
| US-20170362203-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362203-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362203-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3229798-A2 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | Beta Pharma, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
| WO-2016094821-A2 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094821-A2 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | ALDH1A1 4299/4885KDM4E 3491/4885MEN1 3224/4885 |
| US-10590111-B2 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | EGFR, ERBB2, ERBB4 | ALDH1A1 2480/4885KDM4E 2675/4885MEN1 4734/4885 |
| US-20200216421-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | EGFR, ERBB2, ERBB4 | ALDH1A1 2480/4885KDM4E 2675/4885MEN1 4734/4885 |
| US-11414401-B2 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | EGFR, ERBB2, ERBB4 | ALDH1A1 2480/4885KDM4E 2675/4885MEN1 4734/4885 |
| US-20170362203-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | EGFR, ERBB2, ERBB4 | ALDH1A1 2480/4885KDM4E 2675/4885MEN1 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.